Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Intern Med ; 61(17): 2671-2675, 2022 Sep 01.
Article in English | MEDLINE | ID: mdl-35135914

ABSTRACT

Pleural effusion is a rare manifestation in synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, which is characterized by the presence of osteoarticular lesions and dermatological involvement. We herein report a 71-year-old man with pleural effusion resulting from SAPHO syndrome. He was successfully treated using corticosteroids and has experienced no recurrence for one year. We should consider SAPHO syndrome when encountering cases of anterior chest pain and pleural fluid.


Subject(s)
Acne Vulgaris , Acquired Hyperostosis Syndrome , Hyperostosis , Osteitis , Pleural Effusion , Synovitis , Acne Vulgaris/pathology , Acquired Hyperostosis Syndrome/complications , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapy , Aged , Humans , Hyperostosis/pathology , Male , Osteitis/pathology , Pleural Effusion/diagnostic imaging , Pleural Effusion/etiology , Synovitis/diagnosis , Synovitis/diagnostic imaging
2.
Intern Med ; 60(18): 2887-2897, 2021.
Article in English | MEDLINE | ID: mdl-34526442

ABSTRACT

Objective To identify factors associated with pneumomediastinum during management of connective tissue disease (CTD)-related interstitial lung disease (ILD). Methods Patients diagnosed with pneumomediastinum after the initiation of corticosteroid therapy for their CTD-ILD were enrolled. The baseline characteristics of patients who developed pneumomediastinum after the initiation of corticosteroid therapy (n=13, all occurring within 120 days) were compared to those of patients who did not develop pneumomediastinum (n=49). A multivariate logistic regression analysis was performed to identify factors associated with pneumomediastinum. A receiver operating characteristic (ROC) curve analysis was also performed to assess the predictive performance. Results The body mass index (BMI) [odds ratio (OR) (95% confidence interval (CI)) 0.482 (0.272-0.853)] and serum lactate dehydrogenase (LDH) [OR (95% CI) 1.013 (1-1.025)] levels at baseline were identified as independent factors associated with pneumomediastinum after corticosteroid initiation. The optimal cut-off points of the BMI and LDH levels for predicting pneumomediastinum development, as estimated by the Youden index, were 20.2 kg/m2 and 378 U/L, respectively. LDH showed a sensitivity of 61.5% and the highest specificity of 87.8%. Importantly, combining these markers resulted in the highest sensitivity of 100% and a specificity of 71.4%. Conclusion A low BMI and high serum LDH levels at baseline are useful predictive factors for pneumomediastinum development in CTD-ILD patients.


Subject(s)
Connective Tissue Diseases , Lung Diseases, Interstitial , Mediastinal Emphysema , Biomarkers , Connective Tissue Diseases/complications , Humans , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/epidemiology , Mediastinal Emphysema/diagnostic imaging , Mediastinal Emphysema/etiology , Prognosis , Retrospective Studies
3.
Mod Rheumatol ; 31(6): 1107-1112, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33496215

ABSTRACT

OBJECTIVES: The primary objective is to reveal the effect of hydroxychloroquine (HCQ) treatment on corrected QT (QTc) interval in patients with systemic lupus erythematosus (SLE). The secondary objective is to investigate factors that affect QTc prolongation. METHODS: SLE patients who had electrocardiograms between 2015 and 2020 were recruited and assigned to two groups based on whether they were treated with HCQ (HCQ group) or not (control group). Change of QTc before and after HCQ administration in the HCQ group was measured and compared with the control group. Patients treated with HCQ were further divided into two groups based on presence or absence of QTc prolongation and the characteristics were compared. RESULTS: In total, 126 patients were recruited, of whom 42 were treated with HCQ. In the HCQ group, the mean QTc significantly increased (p < .001), while there was no significant difference of mean QTc in the control group. Moreover, those in the HCQ group with QTc prolongation showed a significantly higher proportion of hypertension and longer SLE duration compared to those without QTc prolongation. However, the multiple logistic regression analysis showed that there were no significant differences among them. CONCLUSION: HCQ could induce QTc prolongation in SLE patients. It might be better that the possibility of QTc prolongation was taken into consideration when HCQ was administered in the patients with longer disease duration of SLE and coincidence of hypertension.


Subject(s)
Antirheumatic Agents , Long QT Syndrome , Lupus Erythematosus, Systemic , Antirheumatic Agents/adverse effects , Electrocardiography , Humans , Hydroxychloroquine/adverse effects , Long QT Syndrome/chemically induced , Long QT Syndrome/diagnosis , Long QT Syndrome/drug therapy , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy
4.
Mod Rheumatol ; 31(6): 1129-1134, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33480825

ABSTRACT

OBJECTIVES: We compared large vessel vasculitis (LVV) clinical features between age groups. METHODS: We retrospectively examined clinical features and therapies in 41 LVV patients at our hospital from January 2010 to March 2020. We compared two patient groups, elderly (≥50 years) and young (<50 years). RESULTS: Of all patients, 29 were elderly and 12 were young. In the younger group, upper extremity symptoms (p <.05), bruits (p <.01), and cardiovascular complications (p <.01) were more common. Of the elderly group, 7 (24%) met classification criteria for giant cell arteritis while none of the younger group met these criteria; however, 10 (83%) of the younger group and 3 (10%) of the elderly group met the ACR classification criteria for Takayasu arteritis (p <.01). In the elderly group, 16 patients (66%) met no criteria (p <.01). There were no significant differences in laboratory findings but imaging showed a significantly higher incidence of head and neck artery lesions in the younger group (p <.05). The younger group was more likely to receive additional tocilizumab (p <.01) and cardiovascular complications were more likely to occur in younger patients (p < .01). CONCLUSION: LVV clinical features differed between elderly- and young-age-onset groups.


Subject(s)
Age Factors , Age of Onset , Giant Cell Arteritis , Takayasu Arteritis , Aged , Aged, 80 and over , Female , Giant Cell Arteritis/complications , Giant Cell Arteritis/diagnosis , Giant Cell Arteritis/drug therapy , Humans , Male , Middle Aged , Retrospective Studies , Takayasu Arteritis/diagnosis , Takayasu Arteritis/diagnostic imaging , Young Adult
8.
Mod Rheumatol ; 31(3): 636-642, 2021 May.
Article in English | MEDLINE | ID: mdl-32930047

ABSTRACT

OBJECTIVES: To investigate the clinical features and prognosis of nocardiosis complicated by connective tissue diseases (CTDs). METHODS: We examined patients with CTDs who were diagnosed with nocardiosis from October 2004 to 2019. We retrospectively investigated patient characteristics and therapeutic outcomes. We then performed a comparison between survivors and non-survivors. RESULTS: Fourteen patients were examined. Underlying CTDs were systemic lupus erythematosus (28.6%), vasculitis syndrome (28.6%), rheumatoid arthritis (21.4%), adult Still disease (14.3%) and dermatomyositis (7.1%). Infected organs were lung (85.7%), brain (42.9%), skin/cutaneous lesions (28.6%) and muscle (7.1%). Disseminated infections were seen in nine patients (64.3%). At the onset of nocardiosis, all patients were given prednisolone (23.2 ± 11.9 mg/day). Only two patients (14.3%) were given TMP-SMX for prophylaxis of pneumocystis pneumonia. Relapse occurred in one patient (7.1%) and four patients (28.6%) died from nocardiosis for a cumulative survival rate at 52 weeks of 76.9%. In a comparison of survivors (71.4%) and non-survivors (28.6%), cutaneous lesions were significantly more frequent in the latter (10 vs 75%, p = .04) with an odds ratio of 27.0 (95% CI: 1.7-453.4). CONCLUSION: Cutaneous lesions as a result of dissemination might be a risk factor for nocardiosis mortality in patients with CTDs.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Arthritis, Rheumatoid/complications , Lupus Erythematosus, Systemic/complications , Nocardia Infections/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Vasculitis/complications , Adult , Anti-Bacterial Agents/adverse effects , Female , Humans , Male , Middle Aged , Nocardia Infections/complications , Nocardia Infections/pathology , Prognosis , Retrospective Studies , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects
9.
Intern Med ; 59(24): 3235-3238, 2020 Dec 15.
Article in English | MEDLINE | ID: mdl-32788531

ABSTRACT

Thrombotic microangiopathy (TMA) is a rare but life-threatening complication of systemic lupus erythematosus (SLE) and is associated with adverse pregnancy outcomes. We herein report a 30-year-old pregnant woman with SLE complicated by TMA. Because her condition was unresponsive to initial corticosteroid and fresh-frozen plasma infusion treatment, we attempted plasma exchange (PE). Although thrombocytopenia and microangiopathic hemolytic anemia gradually improved, fetal death was confirmed at 23 weeks of gestation. This case suggests that PE is an effective therapeutic option but might be insufficient to maintain pregnancy in patients with SLE complicated by TMA.


Subject(s)
Lupus Erythematosus, Systemic , Purpura, Thrombotic Thrombocytopenic , Thrombotic Microangiopathies , Adult , Female , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/therapy , Plasma Exchange , Pregnancy , Pregnancy Outcome , Purpura, Thrombotic Thrombocytopenic/complications , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/therapy , Thrombotic Microangiopathies/diagnosis , Thrombotic Microangiopathies/etiology , Thrombotic Microangiopathies/therapy
10.
Rheumatol Int ; 40(10): 1725-1732, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32206878

ABSTRACT

IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition characterized by increased serum IgG4 level, infiltration of lymphocytes and IgG4-positive (IgG4+) plasma cells and fibrosis. It can occur in almost all organs, commonly affecting the pancreas, biliary tract, salivary and lacrimal glands and kidneys. However, reports of IgG4-RD accompanied by pathologically confirmed, IgG4-related pleural disease are scarce. Here, we present a case of a 64-year-old man with suspected malignant pleural mesothelioma based on imaging findings but finally diagnosed with IgG4-RD (including pleuritis, periaortitis and bilateral submandibular gland enlargement) based on a high serum IgG4 level and pleural histopathological findings such as lymphoplasmacytic infiltration including IgG4+ plasma cells and fibrosis. Systemic corticosteroid therapy was effective at reducing serum IgG4, improving bilateral submandibular gland enlargement, and regressing pleural thickening and periaortic soft tissue. We also discuss clinical characteristics and pleural pathological features of previously reported cases with IgG4-related pleural disease based on a comprehensive literature review. Our case of IgG4-RD with pleura, aorta and submandibular gland involvement, pathologically confirmed by pleural specimen might be unique and very rare.


Subject(s)
Aortitis/pathology , Immunoglobulin G4-Related Disease/diagnosis , Submandibular Gland/pathology , Adult , Aged , Aortitis/diagnosis , Aortitis/drug therapy , Aortitis/etiology , Diagnosis, Differential , Female , Glucocorticoids/administration & dosage , Humans , Immunoglobulin G4-Related Disease/drug therapy , Immunoglobulin G4-Related Disease/pathology , Male , Mesothelioma, Malignant/diagnosis , Middle Aged , Pleura/pathology , Prednisolone/administration & dosage
11.
Mod Rheumatol ; 30(2): 365-372, 2020 Mar.
Article in English | MEDLINE | ID: mdl-30794003

ABSTRACT

Background: Although anti-cyclic citrullinated peptide antibody (anti-CCP Ab) is reported to be found in 5-20% of patients with psoriatic arthritis (PsA), its clinical significance has not been elucidated.Objective: To clarify the association of anti-CCP Ab with clinical features in PsA.Methods: Patients were enrolled who fulfilled the classification criteria for psoriatic arthritis (CASPAR) criteria and visited our hospital. We retrospectively compared clinical characteristics between those who were positive and negative for anti-CCP Ab and further compared changes in disease activity in the patients treated with biological disease-modifying anti-rheumatic drugs (DMARDs).Results: We examined 41 patients (11 females), seven were anti-CCP Ab-positive and 34 were negative. Age (55.0 ± 15.1 years old) and frequency of lung involvements (71.4%) in the anti-CCP Ab-positive group were significantly higher than those (40.0 ± 16.0 and 0%, respectively) in the negative group (p < .05). Rheumatoid factor (RF) titer (749.4 ± 860.7 U/mL) and MMP-3 (604.8 ± 1060.6) in the anti-CCP Ab-positive group was significantly higher than that (3.6 ± 4.4 U/mL and 111.2 ± 77.4, respectively) in the negative group (p < .05). Five patients were treated with tumor necrosis factor (TNF) inhibitors (infliximab (IFX): 3 and adalimumab (ADA): 2) in the anti-CCP Ab-positive group, while in the negative group there were 11 (IFX: 6, ADA: 4, and etanercept (ETN): 1). Within 6 months of treatment, arthritis did not improve with TNF inhibitors in the anti-CCP Ab-positive group, whereas it improved significantly in the negative group.Conclusion: In patients with PsA, anti-CCP Ab might be related to lung involvements, elderly onset, RF and MMP-3 titers, and resistance to TNF inhibitor.


Subject(s)
Anti-Citrullinated Protein Antibodies/blood , Arthritis, Psoriatic/blood , Adult , Aged , Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/pathology , Biomarkers/blood , Drug Resistance , Female , Humans , Male , Middle Aged , Tumor Necrosis Factor-alpha/antagonists & inhibitors
13.
Intern Med ; 57(13): 1935-1938, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-29491297

ABSTRACT

Patients with clinically amyopathic dermatomyositis (CADM), a subset of dermatomyositis characterized by a lack of muscle involvement, frequently develop rapidly progressive and treatment-resistant interstitial lung disease. We report the case of a 49-year-old man who was diagnosed with CADM. He developed interstitial pneumonia, which did not respond to combination therapy with methylprednisolone pulse therapy, cyclophosphamide, and cyclosporine. We therefore attempted plasma exchange. After 7 courses of therapeutic plasma exchange, the interstitial pneumonia gradually improved. This case suggests that plasma exchange might be an effective therapeutic option for patients with progressive interstitial lung disease in steroid- and immunosuppressive therapy-refractive CADM.


Subject(s)
Dermatomyositis/complications , Dermatomyositis/therapy , Lung Diseases, Interstitial/classification , Lung Diseases, Interstitial/therapy , Plasma Exchange/methods , Humans , Male , Middle Aged
14.
Intern Med ; 57(7): 1033-1038, 2018 Apr 01.
Article in English | MEDLINE | ID: mdl-29269680

ABSTRACT

Adult-onset Still disease (AOSD) is a systemic inflammatory disease characterized by fever, arthritis and rash. Corticosteroids represent a promising therapeutic option for AOSD; however, some resistant cases require immunosuppressants and biologic agents. We herein report the case of a 29-year-old Japanese man with severe AOSD, accompanied by constrictive pericarditis (CP) and pleuritis. Although 2 courses of steroid pulse and subsequent high-dose of prednisolone and cyclosporine A improved the patient's CP and pleuritis, his fever and inflammatory responses persisted. Tocilizumab (TCZ) was added to his treatment, which resulted in a rapid remission. This case suggests the usefulness of TCZ in the treatment of severe AOSD with CP and pleuritis.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antirheumatic Agents/therapeutic use , Cyclosporine/therapeutic use , Pericarditis, Constrictive/drug therapy , Pleurisy/drug therapy , Still's Disease, Adult-Onset/complications , Still's Disease, Adult-Onset/drug therapy , Adult , Asian People , Humans , Male , Pericarditis, Constrictive/etiology , Pleurisy/etiology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...